Table 2 Comparison between survivors and patients who died in the ICU
From: Temporary ICUs during the COVID-19 pandemic first wave: description of the cohort at a French centre
Survivors (N = 38) | Deceased in the ICU (N = 21) | p | ||
|---|---|---|---|---|
Epidemiological data | ||||
Age, years, median [IQR] | 54.5 [46.3-60.5] | 59 [51-68] | 0.11 | |
Male sex, n (%) | 27 (71) | 14 (66.7) | 0.77 | |
Body Mass Index (kg/m2), median [IQR] | 26.4 [23.4-29.4] | 30.2 [26.4-35.4] | 0.04 | |
Severity on admission | ||||
SOFA score, median [IQR] | 4.5 [3-6] | 5 [4-7] | 0.11 | |
SAPS II score, median [IQR] | 35 [25.5-42] | 51 [45-60] | < 0.01 | |
Tomodensitometric data | ||||
Chest CT-scan, n (%) | 34 (89.5) | 8 (38.1) | < 0.01 | |
Chest CT degree of involvement | Minimal < 25% | 4 (11.8) | 1 (12.5) | 0.55 |
Mild 25-50% | 20 (58.8) | 3 (37.5) | ||
Moderate or severe > 50% | 10 (29.4) | 4 (50) | ||
Ventilator features on admission | ||||
Invasive mechanical ventilation, n (%) | 32 (84) | 21 (100) | 0.08 | |
PEEP, cmH2O, median [IQR] | 10 [10-10] | 10 [10-12] | 0.10 | |
FiO2, %, median [IQR] | 100 [62.5-100] | 100 [72.5-100] | 0.50 | |
PaO2/FiO2, median [IQR] | 151.5 [108.8-230.2] | 89.5 [66-146.5] | < 0.01 | |
PaCO2, mmHg, median [IQR] | 41 [38.5-42.3] | 40 [35.3-43.8] | 0.36 | |
Drug therapies | ||||
Antibiotic therapy, n (%) | 37 (97.4) | 20 (95.2) | 1 | |
Before ICU admission, n (%) | 17 (44.7) | 10 (47.6) | 1 | |
During ICU stay, n (%) | 37 (97.4) | 19 (90.5) | 0.29 | |
Antiviral therapy, n (%) | 10 (26.3) | 5 (23.8) | 1 | |
Hydroxychloroquine, n (%) | 3 (7.9) | 3 (14.3) | 0.66 | |
Remdesivir, n (%) | 1 (2.6) | 0 | 1 | |
Lopinavir/ritonavir, n (%) | 7 (18.4) | 2 (9.5) | 0.47 | |
Other, n (%) | 2 (5.3) | 0 | 0.53 | |
Anti-inflammatory treatment, n (%) | 12 (31.6) | 3 (14.3) | 0.34 | |
Dexamethasone, n (%) | 7 (18.4) | 2 (9.5) | 0.47 | |
Anti-IL-1 therapy, n (%) | 1 (2.6) | 1 (4.8) | 1 | |
Others, n (%) | 5 (13.2) | 1 (4.8) | 0.41 | |
Use of adjunct measures and outcome | ||||
Continuous neuromuscular blockers, n (%) | 29 (76.3) | 19 (90.5) | 0.30 | |
Prone positioning, n (%) | 22 (57.9) | 19 (90.5) | 0.02 | |
ECMO, n (%) | 2 (5.2) | 9 (42.9) | < 0.01 | |
Vasopressive therapy, n (%) | 16 (42.1) | 18 (85.7) | < 0.01 | |
Renal replacement therapy for AKI, n (%) | 5 (13.6) | 6 (28.6) | 0.17 | |
Tracheotomy, n (%) | 12 (31.6) | 2 (9.5) | 0.11 | |
Ventilator-associated pneumonia, n (%) | 19 (50) | 11 (52.4) | 1 | |
Interregional transfer | 11 (28.9) | 1 (4.8) | 0.04 | |
Initial management in Temporary ICU | 25 (65.8) | 12 (57.1) | 0.58 | |